924643-04-9Relevant academic research and scientific papers
The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing
Jones, Clifford D.,Andrews, David M.,Barker, Andrew J.,Blades, Kevin,Daunt, Paula,East, Simon,Geh, Catherine,Graham, Mark A.,Johnson, Keith M.,Loddick, Sarah A.,McFarland, Heather M.,McGregor, Alexandra,Moss, Louise,Rudge, David A.,Simpson, Peter B.,Swain, Michael L.,Tam, Kin Y.,Tucker, Julie A.,Walker, Mike
scheme or table, p. 6369 - 6373 (2009/10/01)
The development of a novel series of imidazole pyrimidine amides as cyclin-dependent kinase (CDK) inhibitors is described. Optimisation of inhibitory potency against multiple CDK's (1, 2 and 9) resulted in imidazole pyrimidine amides with potent in vitro anti-proliferative effects against a range of cancer cell lines. Excellent physiochemical properties and large margins against inhibition of CYP isoforms and the hERG ion channel were achieved by modification of lipophilicity and amine basicity. A candidate with disease model activity in human cancer cell line xenografts and with suitable physiochemical and pharmacokinetic profiles for intravenous (iv) dosing was selected for further development as AZD5597.
IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS
-
Page/Page column 135-136, (2010/11/25)
Compounds of formula (I): which possess cell cycle inhibitory activity are described.
